Madrigal Pharmaceuticals Inc (MDGL NASDAQ) stock market data APIs
$301.5408
-3.19(-1.1%)
as of July 2, 2025
Try our APIs with
free plan!
Madrigal Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
Prev. Close
301.5408
Open
298.3495
High
310.621
Low
294.2572
52 wk Range
200.63-377.46
Market Cap
6 665 M
Shares Outstanding
22 203 K
Revenue
317 M
EPS
-3.32
Beta
-1.082
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Madrigal Pharmaceuticals Inc data using free add-ons & libraries
Get Madrigal Pharmaceuticals Inc Fundamental Data
Madrigal Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 317 M
- EBITDA: -423 841 984
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-05
- EPS/Forecast: -6.28
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Madrigal Pharmaceuticals Inc News
New
Madrigal Pharmaceuticals stock to be featured in comparative analysis at upcoming conference
Investing.com - Madrigal Pharmaceuticals (NASDAQ:MDGL), currently trading near $300 with analysts seeing up to 80% upside potential according to InvestingPro data, will present a comparative meta-anal...
JMP Reaffirms Price Target for Madrigal Amid Rezdiffra Growth Potential
Madrigal Pharmaceuticals (NASDAQ:MDGL) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. With a price target of $470, Citizens JMP analysts reiterated their Mark...
Madrigal, Viking among notable gainers after Altimmune’s MASH setback
[Human Internal Digestive Organ Liver Anatomy] magicmine/iStock via Getty Images Madrigal Pharmaceuticals (NASDAQ:MDGL [https://seekingalpha.com/symbol/MDGL]) and Viking Therapeutics (NASDAQ:VKTX [ht...
Madrigal Pharmaceuticals Closer to EU Approval for First MASH Treatment, Rezdiffra
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the best biotech stocks to invest in now. On June 20, Madrigal Pharmaceuticals moved closer to introducing the first treatment for metabolic dysfu...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
